HIGHER IMPACT LC/MS DIAGNOSTICS - AGILENT IN VITRO DIAGNOSTIC MEDICAL DEVICES FOR CLINICAL LABORATORIES

Importance of the Topic

Mass spectrometry combined with liquid chromatography has revolutionized clinical diagnostics by enabling sensitive, specific and quantitative analysis of biomarkers in biological samples. High instrument reliability and regulatory compliance are essential to ensure confidence in patient test results.

Objectives and Study Overview

This document presents Agilent Technologies’ in vitro diagnostic solutions for clinical laboratories. It highlights the development and manufacturing of FDA-compliant Class I LC/MS medical devices, the support infrastructure for method development and routine operation, and financing and service options to optimize laboratory workflows and uptime.

Methodology and Used Instrumentation

Agilent’s clinical LC/MS platform includes:

• 1260 Infinity High Performance Autosampler Clinical Edition
• 1290 Infinity Thermostat Clinical Edition
• 1260 Infinity Binary Pump Clinical Edition
• 1260 Infinity High Performance Degasser Clinical Edition
• 1260 Infinity Thermostatted Column Compartment Clinical Edition
• 6420 and 6460 Triple Quadrupole LC/MS systems equipped with electrospray ionization (ESI) and Jet Stream technology
• MassHunter Acquisition and Quantitative Analysis software integrated with Laboratory Information Systems

All instruments are designed and manufactured under FDA Quality System Regulations (21 CFR Part 820).

Main Results and Discussion

Agilent’s LC components deliver robust chromatography, while the 6420 and 6460 triple quadrupoles provide superior sensitivity and fast polarity switching for complex matrices. Jet Stream ion source enhances desolvation and signal-to-noise ratio. Integrated MassHunter software streamlines data acquisition, review by exception, and reporting. Comprehensive service plans (Gold, Silver, Bronze) and financing options support uninterrupted operation and regulatory compliance.

Benefits and Practical Applications

• Reliable quantitation of analytes in clinical matrices
• Regulatory compliance through FDA-approved design and quality systems
• Enhanced lab efficiency via automated workflows and software integration
• Maximized uptime with tailored service contracts and local support
• Cost management through flexible financing and leasing

Future Trends and Opportunities

• Integration of high-resolution MS for untargeted biomarker discovery
• Automation and robotics for sample preparation and data handling
• Cloud-based data analysis and real-time reporting
• Expanded use of multiplexed assays and high-throughput platforms
• Stricter regulatory frameworks driving further instrument validation

Conclusion

Agilent’s in vitro diagnostic LC/MS solutions combine robust hardware, sensitive detectors, and integrated software with comprehensive service and financing support. This partnership approach ensures clinical laboratories achieve reliable, compliant and efficient workflows for quantitative analysis.

Reference

• Agilent Technologies. In Vitro Diagnostic Medical Devices for Clinical Laboratories brochure. 2017.